This study explains a novel regulatory mechanism of circMET in NONO-TFE3 tRCC, which might provide novel insights for better tailoring treatment and identification of new therapeutic targets, such as targeted therapy using small RNA and detection kit based on CRISPR/Cas12. This evidence concerns the gene TFE3 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.